Biopharmx (BPMX) Issues Quarterly Earnings Results, Meets Expectations

Biopharmx (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02), Bloomberg Earnings reports.

Shares of NYSEAMERICAN BPMX opened at $0.16 on Friday. Biopharmx has a one year low of $0.10 and a one year high of $0.38.

In other news, Director Anja B. Krammer sold 500,000 shares of the company’s stock in a transaction on Friday, October 12th. The shares were sold at an average price of $0.19, for a total transaction of $95,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Morlock sold 1,125,027 shares of the company’s stock in a transaction on Monday, October 22nd. The stock was sold at an average price of $0.18, for a total transaction of $202,504.86. The disclosure for this sale can be found here.

COPYRIGHT VIOLATION NOTICE: “Biopharmx (BPMX) Issues Quarterly Earnings Results, Meets Expectations” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Further Reading: When is a capital gain realized?

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.

Leave a Reply